{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T11:09:27Z","timestamp":1770980967374,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd012815.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000}}],"reference-count":276,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012815.pub3","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T13:12:25Z","timestamp":1656508345000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Marine-derived n-3 fatty acids therapy for stroke"],"prefix":"10.1002","volume":"2022","author":[{"given":"Celia Gabriela","family":"Alvarez Campano","sequence":"additional","affiliation":[{"name":"The Rowett Institute; University of Aberdeen; Aberdeen UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Joan","family":"Macleod","sequence":"additional","affiliation":[{"name":"Institute of Medical Sciences; Polwarth Building; Aberdeen UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorna","family":"Aucott","sequence":"additional","affiliation":[{"name":"Health Services Research Unit; University of Aberdeen; Aberdeen UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Thies","sequence":"additional","affiliation":[{"name":"The Rowett Institute; University of Aberdeen; Aberdeen UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"issue":"12","key":"10.1002\/14651858.CD012815.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"e81519","DOI":"10.1371\/journal.pone.0081519","article-title":"Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega trial","volume":"8","author":"Brouwer","year":"2013","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1002\/14651858.CD012815.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3390\/nu9111233","article-title":"Effect of omega-3 fatty acid supplementation on plasma fibroblast growth factor 23 levels in post-myocardial infarction patients with chronic kidney disease: the Alpha Omega trial","volume":"9","author":"Borst","year":"2017","journal-title":"Nutrients"},{"issue":"1","key":"10.1002\/14651858.CD012815.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/2047487317739986","article-title":"Body-fat indicators and kidney function decline in older post-myocardial infarction patients: The Alpha Omega Cohort Study","volume":"25","author":"Esmeijer","year":"2018","journal-title":"European Journal of Preventive Cardiology"},{"issue":"13","key":"10.1002\/14651858.CD012815.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/eurheartj\/ehr499","article-title":"Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction","volume":"33","author":"Eussen","year":"2012","journal-title":"European Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD012815.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jalz.2011.06.002","article-title":"Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients","volume":"8","author":"Geleijnse","year":"2012","journal-title":"Alzheimer's & Dementia"},{"issue":"4","key":"10.1002\/14651858.CD012815.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ahj.2009.12.033","article-title":"Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial","volume":"159","author":"Geleijnse","year":"2010","journal-title":"American Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD012815.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1365-2605.2012.01255.x","article-title":"No effects of n-3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial","volume":"35","author":"Giltay","year":"2012","journal-title":"International Journal of Andrology"},{"issue":"6","key":"10.1002\/14651858.CD012815.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3945\/ajcn.111.018259","article-title":"Effects of n-3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction","volume":"94","author":"Giltay","year":"2011","journal-title":"American Journal of Clinical Nutrition"},{"issue":"2","key":"10.1002\/14651858.CD012815.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"e0171868","DOI":"10.1371\/journal.pone.0171868","article-title":"Kidney function and specific mortality in 60-80 years old post-myocardial infarction patients: a 10-year follow-up study","volume":"12","author":"Hoogeveen","year":"2017","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1002\/14651858.CD012815.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1177\/2047487313494295","article-title":"No effect of n-3 fatty acids on high-sensitivity C-reactive protein after myocardial infarction: the Alpha Omega Trial","volume":"21","author":"Hoogeveen","year":"2014","journal-title":"European Journal of Preventive Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD012815.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.2215\/CJN.10441013","article-title":"Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial","volume":"9","author":"Hoogeveen","year":"2014","journal-title":"Clinical Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD012815.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1177\/2047487314536694","article-title":"No effect of n-3 fatty acids supplementation on NT-proBNP after myocardial infarction: the Alpha Omega Trial","volume":"22","author":"Hoogeveen","year":"2015","journal-title":"European Journal of Preventive Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD012815.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.2337\/dc11-0896","article-title":"N-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes","volume":"34","author":"Kromhout","year":"2011","journal-title":"Diabetes Care"},{"issue":"21","key":"10.1002\/14651858.CD012815.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMoa1003603","article-title":"n-3 fatty acids and cardiovascular events after myocardial infarction","volume":"363","author":"Kromhout","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012815.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3945\/ajcn.117.157826","article-title":"Dietary fatty acid intake after myocardial infarction: a theoretical substitution analysis of the Alpha Omega Cohort","volume":"106","author":"Molenberg","year":"2017","journal-title":"American Journal of Clinical Nutrition"},{"issue":"3","key":"10.1002\/14651858.CD012815.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/2047487312438184","article-title":"Physical activity after myocardial infarction: is it related to mental health?","volume":"20","author":"Rius-Ottenheim","year":"2012","journal-title":"European Journal of Preventive Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD012815.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"e0186368","DOI":"10.1371\/journal.pone.0186368","article-title":"Dietary patterns and mental health after myocardial infarction","volume":"12","author":"Rius-Ottenheim","year":"2017","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1002\/14651858.CD012815.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3945\/ajcn.115.112276","article-title":"Healthy eating and lower mortality risk in a large cohort of cardiac patients who received state-of-the-art drug treatment","volume":"102","author":"Sijtsma","year":"2015","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12471-012-0248-z","article-title":"Levels and trends in cardiovascular risk factors and drug treatment in 4837 elderly Dutch myocardial infarction patients between 2002 and 2006","volume":"20","author":"Soedamah-Muthu","year":"2012","journal-title":"Netherlands Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD012815.pub3-BIB0020|cit20","first-page":"e001360","article-title":"Cardiovascular risk factor management of myocardial infarction patients with and without diabetes in the Netherlands between 2002 and 2006: a cross-sectional analysis of baseline data","volume":"2","author":"Soedamah-Muthu","year":"2012","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD012815.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3945\/ajcn.117.153338","article-title":"Coffee consumption after myocardial infarction and risk of cardiovascular mortality: a prospective analysis in the Alpha Omega Cohort","volume":"106","author":"Dongen","year":"2017","journal-title":"American Journal of Clinical Nutrition"},{"issue":"3","key":"10.1002\/14651858.CD012815.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ijcard.2014.08.055","article-title":"Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study","volume":"176","author":"Doi","year":"2014","journal-title":"International Journal of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD012815.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1161\/01.CIR.94.7.1553","article-title":"Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty","volume":"94","author":"Cairns","year":"1996","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD012815.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mhj.2002.121805","article-title":"Prevention of postcoronary angioplasty restenosis by omega-3 fatty acids: main results of the Esapent for Prevention of Restenosis ITalian Study (ESPRIT)","volume":"143","author":"Maresta","year":"2002","journal-title":"American Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD012815.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.amjcard.2011.04.036","article-title":"Effect of dietary fish oil on atrial fibrillation after cardiac surgery","volume":"108","author":"Farquharson","year":"2011","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2369-10-1","article-title":"Preventing AVF thrombosis: the rationale and design of the omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study","volume":"10","author":"Irish","year":"2009","journal-title":"BMC Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD012815.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamainternmed.2016.8029","article-title":"Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis. A randomized clinical trial","volume":"177","author":"Irish","year":"2017","journal-title":"JAMA Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012815.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/nep.12573","article-title":"Baseline characteristics of the omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study","volume":"21","author":"Viecelli","year":"2016","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12882-015-0089-2","article-title":"The omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications","volume":"16","author":"Viecelli","year":"2015","journal-title":"BioMed Central Nephrology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0030|cit30","unstructured":"Fish oils (Omega 3) in ischaemic stroke www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=211&isReview=true"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0031|cit31","first-page":"623","article-title":"The fish oils in ischemic stroke (FOILS) study: a randomised controlled trial","volume":"39","author":"Anderson","year":"2008","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1161\/STROKEAHA.109.555136","article-title":"Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial","volume":"40","author":"Poppitt","year":"2009","journal-title":"Stroke"},{"issue":"1","key":"10.1002\/14651858.CD012815.pub3-BIB0033|cit33","first-page":"11","article-title":"Effectiveness and safety of omega-3 fatty acids for the prevention of ischemic complications following carotid artery stenting: an early terminated pilot study","volume":"17","author":"Foroughinia","year":"2018","journal-title":"Iranian Journal of Neurology"},{"issue":"23","key":"10.1002\/14651858.CD012815.pub3-BIB0034|cit34","first-page":"2780","article-title":"Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of a double-blind randomized clinical trial (FORWARD)","volume":"126","author":"Macchia","year":"2012","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD012815.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2012.11.021","article-title":"Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation. Results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) Trial","volume":"61","author":"Macchia","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD012815.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ahj.2008.10.027","article-title":"The rationale and design of the FOR\u03c9ARD Trial: a randomized, double-blind, placebo-controlled, independent study to test the efficacy of n-3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation","volume":"157","author":"Macchia","year":"2009","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0037|cit37","unstructured":"Randomized trial to assess efficacy of PUFA for the maintenance of sinus rhythm in persistent atrial fibrillation (FORWARD) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00597220"},{"issue":"1","key":"10.1002\/14651858.CD012815.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.nutres.2011.12.007","article-title":"Low dose fish oil supplementation increases serum adiponectin without affecting inflammatory markers in overweight subjects","volume":"32","author":"Gammelmark","year":"2012","journal-title":"Nutrition Research (New York, N.Y.)"},{"issue":"1","key":"10.1002\/14651858.CD012815.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.plefa.2012.05.009","article-title":"The effect of low-dose marine n-3 fatty acids on the biosynthesis of pro-inflammatory 5-lipoxygenase pathway metabolites in overweight subjects: a randomized controlled trial","volume":"87","author":"Nielsen","year":"2012","journal-title":"Prostaglandins, Leukotrienes, and Essential Fatty Acids"},{"issue":"9","key":"10.1002\/14651858.CD012815.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.3390\/md11093324","article-title":"The effect of low-dose marine n-3 fatty acids on plasma levels of scd36 in overweight subjects: a randomized, double-blind, placebo-controlled trial","volume":"11","author":"Ven\u00f8","year":"2013","journal-title":"Marine Drugs"},{"issue":"17","key":"10.1002\/14651858.CD012815.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1161\/CIRCULATIONAHA.114.013760","article-title":"Risk of stroke in chronic heart failure patients without atrial fibrillation analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials","volume":"131","author":"Abdul-Rahim","year":"2015","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/14651858.CD012815.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurjhf\/hft103","article-title":"n-3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI-HF trial","volume":"15","author":"Aleksova","year":"2013","journal-title":"European Journal of Heart Failure"},{"issue":"2","key":"10.1002\/14651858.CD012815.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ahj.2010.10.032","article-title":"Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: a substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Insufficienza Cardiaca (GISSI-HF) trial","volume":"161","author":"Finzi","year":"2011","journal-title":"American Heart Journal"},{"issue":"12","key":"10.1002\/14651858.CD012815.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurjhf\/hfq172","article-title":"Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial","volume":"12","author":"Ghio","year":"2010","journal-title":"European Journal of Heart Failure"},{"issue":"9645","key":"10.1002\/14651858.CD012815.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"GISSI-HF investigators","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"GISSI-HF investigators","year":"2008","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD012815.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.nutres.2016.06.012","article-title":"Red blood cell oleic acid levels reflect olive oil intake while omega-3 levels reflect fish intake and the use of omega-3 acid ethyl esters: the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Heart Failure trial","volume":"36","author":"Harris","year":"2016","journal-title":"Nutrition Research"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/eurjhf\/hfs126","article-title":"Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI-HF trial","volume":"14","author":"La Rovere","year":"2012","journal-title":"European Journal of Heart Failure"},{"issue":"2","key":"10.1002\/14651858.CD012815.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.hrthm.2012.10.035","article-title":"n-3PUFA and holter-derived autonomic variables in patients with heart failure: data from the gruppo italiano per to studio delta sopravvivenza nell'insufficienza cardiaca (GISSI-HF) holter substudy","volume":"10","author":"La Rovere","year":"2013","journal-title":"Hearth Rhythm"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/eurheartj\/ehp357","article-title":"Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial","volume":"30","author":"Maggioni","year":"2009","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.metabol.2018.02.007","article-title":"Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: a post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial","volume":"83","author":"Mantovani","year":"2018","journal-title":"Metabolism Clinical and Experimental"},{"issue":"2","key":"10.1002\/14651858.CD012815.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ahj.2012.10.021","article-title":"Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure trial: relation with fish intake, circulating biomarkers, and mortality","volume":"165","author":"Masson","year":"2013","journal-title":"American Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD012815.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ahj.2012.10.021","article-title":"Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality","volume":"165","author":"Masson","year":"2013","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0054|cit54","unstructured":"GISSI-HF- Effects of n-3 PUFA and rosuvastatin on mortality-morbidity of patients with symptomatic CHF https:\/\/www.clinicaltrials.gov\/ct2\/show\/record\/NCT00336336"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pupt.2017.03.001","article-title":"Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: a sub-analysis of GISSI-HF trial","volume":"44","author":"Rossi","year":"2017","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD012815.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ejheart.2004.03.001","article-title":"Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure","volume":"6","author":"Tavazzi","year":"2004","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0057|cit57","first-page":"309A","article-title":"A double-blind, placebo-controlled trial of MaxEpa in stroke patients","volume":"32","author":"Green","year":"1984","journal-title":"Clinical Research"},{"issue":"4","key":"10.1002\/14651858.CD012815.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/01.STR.16.4.706","article-title":"A double-blind, placebo-controlled trial of fish oil concentrate (MaxEpa) in stroke patients","volume":"16","author":"Green","year":"1985","journal-title":"Stroke"},{"issue":"2","key":"10.1002\/14651858.CD012815.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5551\/jat.5876","article-title":"Relationships between plasma fatty acid composition and coronary artery disease","volume":"18","author":"Ikatura","year":"2011","journal-title":"Journal of Atherosclerosis and Thrombosis"},{"issue":"7","key":"10.1002\/14651858.CD012815.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"673","DOI":"10.5551\/jat.11593","article-title":"The change in low-density lipoprotein cholesterol concentration is positively related to plasma docosahexaenoic acid but not eicosapentaenoic acid","volume":"19","author":"Ikatura","year":"2012","journal-title":"Journal of Atherosclerosis and Thrombosis"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1253\/circj.CJ-09-0520","article-title":"Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease - subanalysis of the JELIS Trial","volume":"74","author":"Ishikawa","year":"2010","journal-title":"Circulation Journal"},{"issue":"7","key":"10.1002\/14651858.CD012815.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1253\/circj.CJ-08-1197","article-title":"Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease-secondary prevention analysis from JELIS","volume":"73","author":"Matsuzaki","year":"2009","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0063|cit63","unstructured":"Protective effect of EPA on cardiovascular events clinicaltrials.gov\/ct2\/show\/NCT00231738"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.atherosclerosis.2009.03.029","article-title":"Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS)","volume":"206","author":"Oikawa","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1253\/circj.CJ-09-0746","article-title":"Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia","volume":"74","author":"Origasa","year":"2010","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2008.06.003","article-title":"Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)","volume":"200","author":"Saito","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.5551\/jat.8326","article-title":"Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: subanalysis of the Japan EPA lipid intervention study (JELIS)","volume":"19","author":"Sasaki","year":"2012","journal-title":"Journal of Atherosclerosis and Thrombosis"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1161\/STROKEAHA.107.509455","article-title":"Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial","volume":"7","author":"Tanaka","year":"2008","journal-title":"Stroke"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012815.pub3-BIB0069|cit69","first-page":"65","article-title":"Relationship of ischemic stroke with serum lipid levels, and influence of plasma eicosapentanoic acid (EPA) concentration in patients with hypercholesterolemia","volume":"3","author":"Tanaka","year":"2008","journal-title":"International Journal of Stroke"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0002-8703(03)00367-3","article-title":"Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS)","volume":"146","author":"Yokoyama","year":"2003","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0072|cit72","first-page":"1391","article-title":"Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes","volume":"37","author":"Nosaka","year":"2016","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijcard.2016.11.105","article-title":"Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study","volume":"228","author":"Nosaka","year":"2017","journal-title":"International Journal of Cardiology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0735-1097(16)30574-5","article-title":"Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study","volume":"67","author":"Nosaka","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000207441","article-title":"Is antioxidant and n-3 supplementation able to improve functional status in poststroke patients? Results from the Nutristroke trial","volume":"27","author":"Garbagnati","year":"2009","journal-title":"Cerebrovascular Disease"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0076|cit76","first-page":"2A","article-title":"Long-chain n-3 fatty acids enter advanced atherosclerotic plaques and are associated with decreased inflammation and decreased inflammatory gene expression","volume":"6","author":"Cawood","year":"2006","journal-title":"Proceedings of the Nutrition Society"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.atherosclerosis.2010.05.022","article-title":"Eicosapentaenoic acid (EPA) from highly concentrated n\u22123 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability","volume":"212","author":"Cawood","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0078|cit78","unstructured":"Omacor and placebo in carotid plaque stability clinicaltrials.gov\/ct2\/show\/NCT00294216"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.3390\/md11093569","article-title":"Limited impact of 2g\/day omega-3 fatty acid ethyl esters (Omacor) on plasma lipids and inflammatory markers in patients awaiting carotid endarterectomy","volume":"11","author":"Yusof","year":"2013","journal-title":"Marine Drugs"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0080|cit80","first-page":"346","article-title":"Predictors of 1-year mortality in patients with contemporary optimised guideline-adherent secondary prevention therapy after acute myocardial infarction: results from the OMEGA Study","volume":"33","author":"Bauer","year":"2012","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00392-013-0581-2","article-title":"Predictors of 1-year mortality in patients with contemporary guideline-adherent therapy after acute myocardial infarction: results from the OMEGA study","volume":"102","author":"Liosis","year":"2013","journal-title":"Clinical Research in Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD012815.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1177\/2047487313486040","article-title":"Short-term comprehensive cardiac rehabilitation after AMI is associated with reduced 1-year mortality: results from the OMEGA study","volume":"21","author":"Rauch","year":"2014","journal-title":"European Journal of Preventive Cardiology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1161\/CIRCULATIONAHA.110.948562","article-title":"OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction","volume":"122","author":"Rauch","year":"2010","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10557-006-0495-6","article-title":"Highly purified omega-3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction - aims and methods of the OMEGA-Study","volume":"20","author":"Rauch","year":"2006","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0085|cit85","first-page":"S1","article-title":"Prognostic effect of omega-3 fatty acid supplementation on top of current guideline adjusted therapy of acute myocardial infarction - the OMEGA trial","volume":"17","author":"Rauch","year":"2010","journal-title":"European Journal of Cardiovascular Prevention and Rehabilitation"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0086|cit86","first-page":"S106","article-title":"Prognostic effect of cardiac rehabilitation after acute myocardial infarction - results of the OMEGA-study","volume":"17","author":"Rauch","year":"2010","journal-title":"European Journal of Cardiovascular Prevention and Rehabilitation"},{"issue":"16","key":"10.1002\/14651858.CD012815.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1671-8","DOI":"10.1016\/j.jacc.2009.11.080","article-title":"Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention - the OMEGA-PCI (OMEGA-3 Fatty Acids After PCI to Modify Responsiveness to Dual Antiplatelet Therapy) Study","volume":"55","author":"Gajos","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.numecd.2013.09.011","article-title":"Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A2 in patients with stable angina","volume":"24","author":"Gajos","year":"2014","journal-title":"Nutrition, Metabolism & Cardiovascular Diseases"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1161\/ATVBAHA.111.228593","article-title":"Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI Clot)","volume":"31","author":"Gajos","year":"2011","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10557-013-6457-x","article-title":"Omega-3 polyunsaturated fatty acids increase plasma adiponectin to leptin ratio in stable coronary artery disease","volume":"27","author":"Mostowik","year":"2013","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1161\/CIRCULATIONAHA.120.052209","article-title":"Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction","volume":"143","author":"Kalstad","year":"2021","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"e480","DOI":"10.1161\/CIR.0000000000000940","article-title":"Effects of n-3 fatty acid supplements on clinical outcome after myocardial infarction in the elderly: results of the OMEMI trial","volume":"142","author":"Kalstad","year":"2020","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1471-2318-14-74","article-title":"Effects of omega 3 supplementation in elderly patients with acute myocardial infarction: design of a prospective randomized placebo controlled study","volume":"14","author":"Laake","year":"2014","journal-title":"BMC Geriatrics"},{"issue":"5","key":"10.1002\/14651858.CD012815.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"279","DOI":"10.5414\/CN108285","article-title":"n-3 polyunsaturated fatty acids and adiponectin in patients with end-stage renal disease","volume":"83","author":"Harving","year":"2015","journal-title":"Clinical Nephrology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1017\/S0007114511003771","article-title":"Marine n-3 fatty acids, atrial fibrillation and QT interval in haemodialysis patients","volume":"107","author":"Kirkegaard","year":"2012","journal-title":"British Journal of Nutrition"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.nutres.2010.07.004","article-title":"The content of docosahexaenoic acid in serum phospholipid is inversely correlated with plasma homocysteine levels in patients with end-stage renal disease","volume":"30","author":"Rasmussen","year":"2010","journal-title":"Nutrition Research"},{"issue":"4","key":"10.1002\/14651858.CD012815.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1053\/j.jrn.2015.01.021","article-title":"The effect of n-3 fatty acids on small dense low-density lipoproteins in patients with end-stage renal disease: a randomized placebo-controlled intervention study","volume":"25","author":"S\u00f8rensen","year":"2015","journal-title":"Journal of Renal Nutrition"},{"issue":"4","key":"10.1002\/14651858.CD012815.pub3-BIB0098|cit98","first-page":"459","article-title":"The effect of n-3 fatty acids on levels of methylarginines in patients with end-stage renal disease","volume":"23","author":"Svensson","year":"2010","journal-title":"Journal of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD012815.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.jrn.2007.02.004","article-title":"The effect of n-3 fatty acids on heart rate variability in patients treated with chronic hemodialysis","volume":"17","author":"Svensson","year":"2007","journal-title":"Journal of Renal Nutrition"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1093\/ndt\/gfn180","article-title":"The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study","volume":"23","author":"Svensson","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2215\/CJN.00630206","article-title":"N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial","volume":"1","author":"Svensson","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.3945\/ajcn.2009.29121","article-title":"Effect of 2-y n23 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial","volume":"91","author":"Dangour","year":"2010","journal-title":"American Journal of Clinical Nutrition"},{"issue":"3","key":"10.1002\/14651858.CD012815.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.ophtha.2012.09.043","article-title":"n-3 fatty acids and retinal function","volume":"120","author":"Dangour","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1475-2891-5-20","article-title":"A randomised controlled trial investigating the effect of n-3 long-chain polyunsaturated fatty acid supplementation on cognitive and retinal function in cognitively healthy older people: the Older People And n-3 Long-chain polyunsaturated fatty acids (OPAL) study protocol [ISRCTN72331636]","volume":"5","author":"Dangour","year":"2006","journal-title":"Nutrition Journal"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3390\/nu10091313","article-title":"Effects of marine n-3 polyunsaturated fatty acids on heart rate variability and heart rate in patients on chronic dialysis: a randomized controlled trial","volume":"10","author":"Rantanen","year":"2018","journal-title":"Nutrients"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0106|cit106","unstructured":"Risk and prevention study: evaluation of the efficacy of n-3 PUFA in subjects at high cardiovascular risk clinicaltrials.gov\/ct2\/show\/NCT00317707"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1745-6215-11-68","article-title":"Efficacy of n-3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies inpatients at high cardiovascular risk: rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice","volume":"11","author":"Rischio and Prevenzione Investigators","year":"2010","journal-title":"Trials"},{"issue":"19","key":"10.1002\/14651858.CD012815.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1205409","article-title":"n\u22123 fatty acids in patients with multiple cardiovascular risk factors","volume":"368","author":"The Risk and Prevention Study Collaborative Group","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4103\/sni.sni_266_17","article-title":"Long-chain omega-3 fatty acids in aneurysmal subarachnoid hemorrhage: a randomized pilot trial of pharmaconutrition","volume":"8","author":"Saito","year":"2017","journal-title":"Surgical Neurology International"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0008-6363(02)00229-8","article-title":"Effect of dietary supplementation with \u03c9-3 fatty acids on progression of atherosclerosis in carotid arteries","volume":"54","author":"Angerer","year":"2002","journal-title":"Cardiovascular Research"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0111|cit111","first-page":"125","article-title":"Dietary \u03c9-3 fatty acids and human carotid atherosclerosis in patients with coronary artery disease: results of a randomized, double-blind two-year intervention trial","volume":"19 Suppl 1","author":"Angerer","year":"1998","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"554","DOI":"10.7326\/0003-4819-130-7-199904060-00003","article-title":"The effect of dietary \u03c9-3 fatty acids on coronary atherosclerosis: a randomized, double-blind, placebo-controlled trial","volume":"130","author":"Schacky","year":"1999","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0113|cit113","first-page":"S99","article-title":"The effect of n-3 fatty acids on coronary atherosclerosis: results from SCIMO, an angiographic study, background and implications","volume":"36","author":"Schacky","year":"2001","journal-title":"Lipids"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3945\/ajcn.112.035253","article-title":"Supplementation with B vitamins or n23 fatty acids and depressive symptoms in cardiovascular disease survivors: ancillary findings from the SUpplementation with FOLate, vitamins B-6 and B-12 and\/or OMega-3 fatty acids (SU.FOL.OM3) randomized trial","volume":"96","author":"Andreeva","year":"2012","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3945\/ajcn.110.006320","article-title":"Cognitive function after supplementation with B vitamins and long-chain omega-3 fatty acids: ancillary findings from theSU.FOL.OM3 randomized trial","volume":"94","author":"Andreeva","year":"2011","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"e84844","DOI":"10.1371\/journal.pone.0084844","article-title":"B Vitamin and\/or n-3 fatty acid supplementation and health-related quality of life: ancillary findings from the SU.FOL.OM3 randomized trial","volume":"9","author":"Andreeva","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ijcard.2012.01.060","article-title":"Cardiovascular effects of B-vitamins and\/or N-3 fatty acids: the Su.Fol.Om3 trial","volume":"167","author":"Blacher","year":"2013","journal-title":"International Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD012815.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1017\/S0007114511003692","article-title":"Effect of B-vitamins and n-3 PUFA supplementation for 5 years on blood pressure in patients with CVD","volume":"107","author":"Edelenyi","year":"2012","journal-title":"British Journal of Nutrition"},{"issue":"4","key":"10.1002\/14651858.CD012815.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"e92548","DOI":"10.1371\/journal.pone.0092548","article-title":"Baseline plasma fatty acids profile and incident cardiovascular events in the SU.FOL.OM3 Trial: the evidence revisited","volume":"9","author":"Fezeu","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1745-6215-9-35","article-title":"The SU.FOL.OM3 Study: a secondary prevention trial testing the impact of supplementation with folate and B-vitamins and\/or Omega-3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics","volume":"9","author":"Galan","year":"2008","journal-title":"Trials"},{"issue":"6","key":"10.1002\/14651858.CD012815.pub3-BIB0121|cit121","first-page":"428","article-title":"Background and rationale of the SU.FOL.OM3 study: double-blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and\/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries","volume":"7","author":"Galan","year":"2003","journal-title":"Journal of Nutrition Health and Aging"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"c6273","DOI":"10.1136\/bmj.c6273","article-title":"Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial","volume":"341","author":"Galan","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0123|cit123","unstructured":"Supplementation with folate (and vitamins B6 and B12) and\/or omega 3 fatty acids on the prevention of recurrent ischaemic events in patients who have already experienced a coronary or cerebrovascular event www.isrctn.com\/ISRCTN41926726"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/HJR.0b013e3283383f47","article-title":"Control of baseline cardiovascular risk factors in the SU-FOL-OM3 study cohort: does the localization of the arterial event matter?","volume":"17","author":"Vesin","year":"2010","journal-title":"European Journal of Cardiovascular Prevention and Rehabilitation"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"S345","DOI":"10.1007\/BF02562338","article-title":"Docosahexaenoic acid supplementation improves the moderately severe dementia from thrombotic cerebrovascular diseases","volume":"34","author":"Terano","year":"1999","journal-title":"Lipids"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0126|cit126","first-page":"365","article-title":"Potential of dietary supplementation in patients with carotid artery disease","volume":"89","author":"Rerkasem","year":"2002","journal-title":"British Journal of Surgery"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(03)12468-3","article-title":"Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial","volume":"361","author":"Thies","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"AWP413","DOI":"10.1161\/str.44.suppl_1.AWP413","article-title":"Eicosapentaenoic acid in addition to a strong statin makes regression of intima-media thickness in patients with asymptomatic cerebral infarction","volume":"44","author":"Wakita","year":"2013","journal-title":"Stroke"},{"issue":"4","key":"10.1002\/14651858.CD012815.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/jnnp-2017-316176","article-title":"DHA supplementation improves cognitive function via enhancing A\u03b2-mediated autophagy in Chinese elderly with mild cognitive impairment: a randomised placebo-controlled trial","volume":"89","author":"Zhang","year":"2018","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3233\/JAD-160439","article-title":"Effects of DHA supplementation on hippocampal volume and cognitive function in older adults with mild cognitive impairment: a 12-month randomized, double-blind, placebo-controlled trial","volume":"55","author":"Zhang","year":"2017","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000362535","article-title":"Advice on lifestyle changes (diet, red wine and physical activity) does not affect internal carotid and middle cerebral artery blood flow velocity in patients with carotid atherosclerosis in a randomized controlled trial","volume":"37","author":"Droste","year":"2014","journal-title":"Cerebrovascular Diseases"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1475-2891-12-147","article-title":"A daily glass of red wine associated with lifestyle changes independently improves blood lipids in patients with carotid arteriosclerosis: results from a randomized controlled trial","volume":"12","author":"Droste","year":"2013","journal-title":"Nutrition Journal"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000354847","article-title":"A daily glass of red wine and lifestyle changes do not affect arterial blood pressure and heart rate in patients with carotid arteriosclerosis after 4 and 20 weeks","volume":"3","author":"Droste","year":"2013","journal-title":"Cerebrovascular Diseases Extra"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0134|cit134","unstructured":"Nutrition and physical activity in patients with cerebrovascular disease clinicaltrials.gov\/ct2\/show\/NCT01146132"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacl.2016.02.008","article-title":"Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies","volume":"10","author":"Ballantyne","year":"2016","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","article-title":"Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR Study)","volume":"110","author":"Ballantyne","year":"2012","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jacl.2014.11.009","article-title":"Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)","volume":"9","author":"Ballantyne","year":"2015","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40256-012-0002-3","article-title":"Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies","volume":"13","author":"Bays","year":"2013","journal-title":"American Journal of Cardiovascular Drugs"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.prostaglandins.2016.07.007","article-title":"Icosapent ethyl: eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies","volume":"125","author":"Bays","year":"2016","journal-title":"Prostaglandins & other Lipid Mediators"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1475-2840-12-100","article-title":"Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides(200-500 mg\/dL), and on statin therapy at LDL-Cgoal: the ANCHOR study","volume":"12","author":"Brinton","year":"2013","journal-title":"Cardiovascular Diabetology"},{"issue":"10","key":"10.1002\/14651858.CD012815.pub3-BIB0141|cit141","first-page":"1094","article-title":"Effect of omega-3 fatty acid nutritional therapy on immune function in patients with acute ischemic stroke","volume":"35","author":"Bao","year":"2016","journal-title":"Chinese Journal of Geriatrics"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.numecd.2008.01.006","article-title":"Vitamin C consumption is associated with less progression in carotid intima media thickness in elderly men: a 3-year intervention study","volume":"19","author":"Ellingsen","year":"2009","journal-title":"Nutrition Metabolism & Cardiovascular Diseases"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0143|cit143","first-page":"325","article-title":"Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia","volume":"13","author":"Hjerkinn","year":"2006","journal-title":"European Journal of Cardiovascular Prevention and Rehabilitation"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0144|cit144","unstructured":"Diet and omega-3 intervention trial on atherosclerosis clinicaltrials.gov\/ct2\/show\/NCT00764010"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0145|cit145","unstructured":"Eicosapentaenoic acid cerebral vasospasm therapy study clinicaltrials.gov\/ct2\/show\/NCT00839449"},{"issue":"2","key":"10.1002\/14651858.CD012815.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.wneu.2012.09.020","article-title":"A prospective, multicenter, randomized study of the efficacy of eicosapentaenoic acid for cerebral vasospasm: the EVAS Study","volume":"81","author":"Yoneda","year":"2014","journal-title":"World Neurosurgery"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacl.2016.02.008","article-title":"Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies","volume":"10","author":"Ballantyne","year":"2016","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40256-012-0002-3","article-title":"Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies","volume":"13","author":"Bays","year":"2013","journal-title":"American Journal of Cardiovascular Drugs"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.prostaglandins.2016.07.007","article-title":"Icosapent ethyl: eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies","volume":"125","author":"Bays","year":"2016","journal-title":"Prostaglandins & Other Lipid Mediators"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the multi-center, placebo-controlled, randomized, double-blind, 12-week study with an open-label extension (MARINE) trial)","volume":"108","author":"Bays","year":"2011","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacl.2012.07.001","article-title":"Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)","volume":"6","author":"Bays","year":"2012","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.plefa.2013.07.005","article-title":"Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study)","volume":"89","author":"Braeckman","year":"2013","journal-title":"Prostaglandins, Leukotrienes and Essential Fatty Acids"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012815.pub3-BIB0153|cit153","first-page":"129 (Abst.P101)","article-title":"Effect of eicosapentaenoic\/docosahexaenoic acid for prevention of cerebral vasospasm following aneurysmal subarachnoid hemorrhage","volume":"41","author":"Nakagawa","year":"2016","journal-title":"Cerebrovascular Diseases"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.wneu.2016.12.018","article-title":"\u03c9-3 fatty acids ethyl esters suppress cerebral vasospasm and improve clinical outcome following aneurysmal subarachnoid hemorrhage","volume":"99","author":"Nakagawa","year":"2017","journal-title":"World Neurosurgery"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0155|cit155","unstructured":"Lovaza's effect on clopidogrel in a neuro population clinicaltrials.gov\/ct2\/show\/NCT01526824"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"e000547","DOI":"10.1161\/JAHA.111.000547","article-title":"A randomized, placebo-controlled trial of omega-3 fatty acids for Inhibition of supraventricular arrhythmias after cardiac surgery: the FISH Trial","volume":"1","author":"Sandesara","year":"2012","journal-title":"Journal of the American Heart Association"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1001\/jama.295.22.2613","article-title":"Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators. The study on omega-3 fatty acids and ventricular arrhythmia (SOFA) randomized trial","volume":"295","author":"Brouwer","year":"2006","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/sj.ejcn.1601695","article-title":"Rationale and design of a randomised controlled clinical trial on supplemental intake of n-3 fatty acids and incidence of cardiac arrhythmia: SOFA","volume":"57","author":"Brouwer","year":"2003","journal-title":"European Journal of Clinical Nutrition"},{"issue":"6","key":"10.1002\/14651858.CD012815.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0011-393X(05)80799-4","article-title":"Combination effect of eicosapentaenoic acid and platelet suppressive agents on platelets","volume":"55","author":"Suehiro","year":"1994","journal-title":"Current Therapeutic Research"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1291\/hypres.28.651","article-title":"Do eicosapentaenoic acid supplements attenuate age-related increases in arterial stiffness in patients with dyslipidemia? A preliminary study","volume":"28","author":"Tomiyama","year":"2005","journal-title":"Hypertension Research"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1600-0404.2007.00983.x","article-title":"Does eicosapentaenoic acid (EPA) inhibit cerebral vasospasm in patients after aneurysmal subarachnoid hemorrhage?","volume":"118","author":"Yoneda","year":"2008","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0162|cit162","first-page":"95","article-title":"Effect of extract supplementation status of snakehead fish in the status of the protein, antioxidant, oxidative stress and outcome in acute ischemic stroke","volume":"9 Suppl 3","author":"Hertantows","year":"2014","journal-title":"International Journal of Stroke"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1740774507081218","article-title":"Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study","volume":"4","author":"Lok","year":"2007","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1001\/jama.2012.3473","article-title":"Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized trial","volume":"307","author":"Lok","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD012815.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/09537100802409921","article-title":"The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients","volume":"20","author":"Nomura","year":"2009","journal-title":"Platelets"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1753-0407.2011.00124.x","article-title":"Strategies to detect abnormal glucose metabolism in people at high risk of cardiovascular disease from the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial population","volume":"3","author":"Badings","year":"2011","journal-title":"Journal of Diabetes"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2337\/dc13-1468","article-title":"The association of basal insulin glargine and\/or n-3 fatty acids with incident cancers in patients with dysglycemia","volume":"37","author":"Bordeleau","year":"2014","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1002\/14651858.CD012815.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S2213-8587(14)70062-2","article-title":"Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial","volume":"2","author":"Cukierman-Yaffe","year":"2014","journal-title":"Lancet Diabetes & Endocrinology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1111\/dom.13674","article-title":"Effects of basal insulin glargine and omega-3 on lower limb arterial disease outcome in patients with dysglycaemia: an analysis of the outcome reduction with an initial glargine intervention (ORIGIN) trial","volume":"21","author":"Dagenais","year":"2019","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1161\/CIRCULATIONAHA.115.015744","article-title":"Identifying novel biomarkers for cardiovascular events or death in people with dysglycemia","volume":"132","author":"Gerstein","year":"2015","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2337\/dc16-1682","article-title":"Growth differentiation factor 15 as a novel biomarker for metformin","volume":"40","author":"Gerstein","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s11892-013-0366-z","article-title":"Insulin use early in the course of type 2 diabetes mellitus: the ORIGIN trial","volume":"13","author":"Hanefeld","year":"2013","journal-title":"Current Diabetes Reports"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1464-5491.2009.02915.x","article-title":"Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes","volume":"27","author":"Hanefeld","year":"2010","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jdiacomp.2014.02.012","article-title":"Cost implications of the use of basal insulin glargine in people with early dysglycemia: the ORIGIN trial","volume":"28","author":"Lamy","year":"2014","journal-title":"Journal of Diabetes and Its Complications"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.2337\/dc12-2129","article-title":"Effect of insulin glargine and n-3 FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events","volume":"36","author":"Lonn","year":"2013","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD012815.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ijcard.2014.04.013","article-title":"Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: a subanalysis of the ORIGIN trial","volume":"174","author":"Lopez-Jaramillo","year":"2014","journal-title":"International Journal of Cardiology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2337\/dc15-1676","article-title":"Cardiovascular and other outcomes post intervention with insulin glargine and omega-3 fatty acids (ORIGINALE)","volume":"39","author":"ORIGIN Trial Investigators","year":"2016","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012815.pub3-BIB0178|cit178","first-page":"S516","article-title":"Outcome reduction with an initial glargine intervention and legacy effects (ORIGINALE)","volume":"57","author":"Punthakee","year":"2014","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2337\/dc11-1918","article-title":"Relationship between A1C and fasting plasma glucose in dysglycemia or Type 2 diabetes","volume":"35","author":"Ramachandran","year":"2012","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD012815.pub3-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/1479164117703034","article-title":"The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial","volume":"14","author":"Rautio","year":"2017","journal-title":"Diabetes & Vascular Disease Research"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00125-014-3238-4","article-title":"Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial","volume":"57","author":"Mann","year":"2014","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"The ORIGIN Trial Investigators","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.2337\/dc12-2238","article-title":"Characteristics associated with maintenance of mean A1C < 6.5% in people with dysglycemia in the ORIGIN Trial","volume":"36","author":"The ORIGIN Trial Investigators","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1093\/eurheartj\/eht332","article-title":"Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial","volume":"34","author":"The ORIGIN Trial Investigators","year":"2013","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","article-title":"n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia","volume":"367","author":"The ORIGIN Trial Investigators","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2337\/dc14-1329","article-title":"Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial","volume":"38","author":"The ORIGIN Trial Investigators","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ahj.2007.09.009","article-title":"Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention)","volume":"155","author":"The ORIGIN Trial Investigators","year":"2008","journal-title":"American Heart Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012815.pub3-BIB0188|cit188","first-page":"AMP49","article-title":"Subgroup analysis of icosapent ethyl for hypertriglyceridemia in prevention of non-fatal stroke and overall mortality","volume":"52","author":"Assad","year":"2021","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/j.cjca.2020.07.218","article-title":"Significant cardiovascular benefits of icosapent ethyl from REDUCE-IT","volume":"36","author":"Bhatt","year":"2020","journal-title":"Canadian Journal of Cardiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012815.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"4LB","DOI":"10.2337\/db20-4-LB","article-title":"Substantial cardiovascular benefit from icosapent ethyl in patients with diabetes: REDUCE-IT DIABETES","volume":"69","author":"Bhatt","year":"2020","journal-title":"Diabetes"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012815.pub3-BIB0191|cit191","first-page":"A15091","article-title":"Significant reductions in both adjudicated and investigator-reported ischemic events in REDUCE-IT","volume":"142","author":"Bhatt","year":"2020","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/CIRCULATIONAHA.119.044440","article-title":"REDUCE-IT USA results from the 3146 patients randomized in the United States","volume":"141","author":"Bhatt","year":"2020","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clinical Cardiology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0195|cit195","first-page":"e752","article-title":"The primary results of the REDUCE-IT trial","volume":"138","author":"Bhatt","year":"2018","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012815.pub3-BIB0196|cit196","first-page":"A57","article-title":"Reduction in ischemic stroke with icosapent ethyl - insights from REDUCE-IT","volume":"52","author":"Bhatt","year":"2021","journal-title":"Stroke"},{"issue":"22","key":"10.1002\/14651858.CD012815.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"Effects of icosapent ethyl on total ischemic events","volume":"73","author":"Bhatt","year":"2019","journal-title":"Journal of The American College of Cardiology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1681\/ASN.20203110S121a","article-title":"Benefits of icosapent ethyl across a range of baseline renal function in patients with established cardiovascular disease or diabetes: results of REDUCE-IT RENAL","volume":"31","author":"Majithia","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"17","key":"10.1002\/14651858.CD012815.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"B1","DOI":"10.1016\/j.jacc.2020.09.018","article-title":"Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention: insights from REDUCE-IT PCI","volume":"76","author":"Peterson","year":"2020","journal-title":"Journal of The American College of Cardiology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/CIRCULATIONAHA.120.050276","article-title":"Reduction in revascularization with icosapent ethyl","volume":"143","author":"Peterson","year":"2021","journal-title":"Circulation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012815.pub3-BIB0201|cit201","first-page":"A14997","article-title":"Icosapent ethyl reduces ischemic events in patients with prior coronary artery bypass grafting: REDUCE-IT CABG","volume":"142","author":"Verma","year":"2020","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0202|cit202","first-page":"35 (Abst.P","article-title":"Should eicosapentaenoic acid and\/or atorvastatin influence cardio-ankle vascular index?","volume":"36 Suppl 2","author":"Sengoku","year":"2013","journal-title":"Cerebrovascular Diseases"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0203|cit203","doi-asserted-by":"publisher","first-page":"e479","DOI":"10.1161\/CIR.0000000000000940","article-title":"STRENGTH trial: cardiovascular outcomes with omega-3 carboxylic acids (Epanova) in patients with high vascular risk and atherogenic dyslipidemia","volume":"142","author":"Lincoff","year":"2020","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/clc.23055","article-title":"Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial","volume":"41","author":"Nicholls","year":"2018","journal-title":"Clinical Cardiology"},{"issue":"22","key":"10.1002\/14651858.CD012815.pub3-BIB0205|cit205","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/14651858.CD012815.pub3-BIB0206|cit206","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1001\/jamacardio.2021.1157","article-title":"Association between achieved [omega]-3 fatty acid levels and major adverse cardiovascular outcomes in patients with high cardiovascular risk: a secondary analysis of the STRENGTH trial","volume":"6","author":"Nissen","year":"2021","journal-title":"JAMA Cardiology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ahj.2021.01.018","article-title":"Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)","volume":"235","author":"Ambrosy","year":"2021","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0208|cit208","unstructured":"Omega 3 and ischemic stroke; fish oil as an option (OmegaStroke) https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04386525"},{"issue":"3","key":"10.1002\/14651858.CD012815.pub3-BIB0209|cit209","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003177.pub5","article-title":"Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease","author":"Abdelhamid","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7454","key":"10.1002\/14651858.CD012815.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"GRADE Working Group. Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD012815.pub3-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","article-title":"Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals","volume":"3","author":"Aung","year":"2018","journal-title":"JAMA Cardiology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0212|cit212","volume-title":"NIP - Neurology in Practice: Stroke","author":"Barret","year":"2013"},{"issue":"2","key":"10.1002\/14651858.CD012815.pub3-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1750-3639.2005.tb00513.x","article-title":"Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress","volume":"15","author":"Bazan","year":"2005","journal-title":"Brain Pathology (Zurich, Switzerland)"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"S400","DOI":"10.1194\/jlr.R800068-JLR200","article-title":"Neuroprotectin D1-mediated anti-inflammatory and survival signalling in stroke, retinal degenerations, and Alzheimer's disease","volume":"50","author":"Bazan","year":"2009","journal-title":"Journal of Lipid Research"},{"issue":"12","key":"10.1002\/14651858.CD012815.pub3-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrn3820","article-title":"Polyunsaturated fatty acids and their metabolites in brain function and disease","volume":"15","author":"Bazinet","year":"2014","journal-title":"Nature Reviews. Neuroscience"},{"issue":"9","key":"10.1002\/14651858.CD012815.pub3-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1161\/STROKEAHA.109.555979","article-title":"Robust docosahexaenoic acid-mediated neuroprotection in a rat model of transient focal cerebral ischemia","volume":"40","author":"Belayev","year":"2009","journal-title":"Stroke"},{"issue":"1","key":"10.1002\/14651858.CD012815.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12975-010-0046-0","article-title":"Docosahexaenoic acid therapy of experimental stroke","volume":"2","author":"Belayev","year":"2011","journal-title":"Translational Stroke Research"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.biochi.2015.06.005","article-title":"The nutraceutical potential of omega-3 alpha-linolenic acid in reducing the consequences of stroke","volume":"120","author":"Blondeau","year":"2016","journal-title":"Biochimie"},{"issue":"5","key":"10.1002\/14651858.CD012815.pub3-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3390\/nu3050529","article-title":"Docosahexaenoic acid (DHA): an ancient nutrient for the modern human brain","volume":"3","author":"Bradbury","year":"2011","journal-title":"Nutrients"},{"issue":"7","key":"10.1002\/14651858.CD012815.pub3-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1161\/STROKEAHA.117.017866","article-title":"The evolution of the modified Rankin Scale and its use in future stroke trials","volume":"48","author":"Broderick","year":"2017","journal-title":"Stroke"},{"issue":"6","key":"10.1002\/14651858.CD012815.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3810\/pgm.2009.11.2083","article-title":"Understanding omega-3 polyunsaturated fatty acids","volume":"121","author":"Calder","year":"2009","journal-title":"Postgraduate Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012815.pub3-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"592S","DOI":"10.3945\/jn.111.155259","article-title":"Mechanisms of action of (n-3) fatty acids","volume":"142","author":"Calder","year":"2012","journal-title":"Journal of Nutrition"},{"issue":"4","key":"10.1002\/14651858.CD012815.pub3-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/HCO.0b013e328353febd","article-title":"Marine omega-3 fatty acids and coronary heart disease","volume":"27","author":"Calder","year":"2012","journal-title":"Current Opinion in Cardiology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0224|cit224","volume-title":"AAN Press Quality of Life Guide: Stroke","author":"Caplan","year":"2006"},{"issue":"6","key":"10.1002\/14651858.CD012815.pub3-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ana.24653","article-title":"Emergent properties of neural repair: elemental biology to therapeutic concepts","volume":"79","author":"Carmichael","year":"2016","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3390\/nu10111662","article-title":"A comprehensive review of chemistry, sources and bioavailability of omega-3 fatty acids","volume":"10","author":"Cholewski","year":"2018","journal-title":"Nutrients"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"e6698","DOI":"10.1136\/bmj.e6698","article-title":"Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis","volume":"345","author":"Chowdhury","year":"2012","journal-title":"BMJ"},{"issue":"8140","key":"10.1002\/14651858.CD012815.pub3-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(79)91490-9","article-title":"Haemostatic function and platelet polyunsaturated fatty acids in Eskimos","volume":"2","author":"Dyerberg","year":"1979","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2013.09.008","article-title":"Docosahexaenoic acid complexed to albumin provides neuroprotection after experimental stroke in aged rats","volume":"62","author":"Eady","year":"2014","journal-title":"Neurobiology of Disease"},{"issue":"11","key":"10.1002\/14651858.CD012815.pub3-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/nm.2507","article-title":"Ischemia and reperfusion - from mechanism to translation","volume":"17","author":"Eltzschig","year":"2011","journal-title":"Nature Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012815.pub3-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/1747493019832996","article-title":"Anthology of stroke epidemiology in the 20th and 21st centuries: assessing the past, the present, and envisioning the future","volume":"14","author":"Feigin","year":"2019","journal-title":"International Journal of Stroke"},{"issue":"7","key":"10.1002\/14651858.CD012815.pub3-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1161\/ATVBAHA.111.228593","article-title":"Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI Clot)","volume":"31","author":"Gajos","year":"2011","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"5","key":"10.1002\/14651858.CD012815.pub3-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/archinte.1996.00440050091010","article-title":"The relationship between fish consumption and stroke incidence. The NHANES I Epidemiologic Follow-up Study (National Health and Nutrition Examination Survey)","volume":"156","author":"Gillum","year":"1996","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0234|cit234","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2015"},{"issue":"13","key":"10.1002\/14651858.CD012815.pub3-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke","volume":"359","author":"Hacke","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0236|cit236","unstructured":"Higgins JPT Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0237|cit237","unstructured":"Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"1-2","key":"10.1002\/14651858.CD012815.pub3-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jns.2013.12.033","article-title":"Docosahexaenoic acid confers enduring neuroprotection in experimental stroke","volume":"338","author":"Hong","year":"2014","journal-title":"Journal of the Neurological Sciences"},{"issue":"14","key":"10.1002\/14651858.CD012815.pub3-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1001\/jama.287.14.1815","article-title":"Fish and omega-3 fatty acid intake and risk of coronary heart disease in women","volume":"287","author":"Hu","year":"2002","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD012815.pub3-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.nut.2012.05.003","article-title":"Comparison of eicosapentaenoic acid concentrations in plasma between patients with ischemic stroke and control subjects","volume":"29","author":"Ikeya","year":"2013","journal-title":"Nutrition"},{"issue":"3","key":"10.1002\/14651858.CD012815.pub3-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jama.285.3.304","article-title":"Intake of fish and omega-3 fatty acids and risk of stroke in women","volume":"285","author":"Iso","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD012815.pub3-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0049-3848(79)90281-0","article-title":"Evidence for the mechanism by which eicosapentaenoic acid inhibits human platelet aggregation and secretion - implications for the prevention of vascular disease","volume":"16","author":"Jakubowski","year":"1979","journal-title":"Thrombosis Research"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(21)01341-6","article-title":"Thrombectomy for anterior circulation stroke beyond 6 h from time last known well (AURORA): a systematic review and individual patient data meta-analysis","volume":"399","author":"Jovin","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD012815.pub3-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/01.STR.25.2.328","article-title":"Fish consumption and risk of stroke. The Zutphen study","volume":"25","author":"Keli","year":"1994","journal-title":"Stroke"},{"issue":"21","key":"10.1002\/14651858.CD012815.pub3-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/01.CIR.0000038493.65177.94","article-title":"Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease","volume":"106","author":"Kris-Etherton","year":"2002","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.plefa.2009.05.011","article-title":"Dietary reference intakes for DHA and EPA","volume":"81","author":"Kris-Etherton","year":"2009","journal-title":"Prostaglandins, Leukotrienes and Essential Fatty Acids"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.plefa.2006.07.010","article-title":"Role of omega-3 fatty acids in brain development and function: potential implications for the pathogenesis and prevention of psychopathology","volume":"75","author":"McNamara","year":"2006","journal-title":"Prostaglandins, Leukotrienes and Essential Fatty Acids"},{"issue":"2","key":"10.1002\/14651858.CD012815.pub3-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/oxfordjournals.aje.a117615","article-title":"Fish consumption and cardiovascular disease in the physicians' health study: a prospective study","volume":"142","author":"Morris","year":"1995","journal-title":"American Journal of Epidemiology"},{"issue":"15","key":"10.1002\/14651858.CD012815.pub3-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1001\/jama.296.15.1885","article-title":"Fish intake, contaminants, and human health: evaluating the risks and the benefits","volume":"296","author":"Mozaffarian","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD012815.pub3-BIB0250|cit250","first-page":"e38","article-title":"Heart disease and stroke statistics - 2016 update","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40169-015-0062-5","article-title":"Eicosapentaenoic acid as long-term secondary prevention after ischemic stroke","volume":"4","author":"Nakase","year":"2015","journal-title":"Clinical and Translational Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012815.pub3-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"11-21","DOI":"10.1056\/NEJMoa1706442","article-title":"Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct","volume":"378","author":"Nogueira","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012815.pub3-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/01.STR.27.2.204","article-title":"Fish consumption and stroke in men","volume":"27","author":"Orencia","year":"1996","journal-title":"Stroke"},{"issue":"1","key":"10.1002\/14651858.CD012815.pub3-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF01401666","article-title":"Increased incidence of bleeding intracranial aneurysms in Greenlandic Eskimos","volume":"67","author":"Ostergaard Kristensen","year":"1983","journal-title":"Acta Neurochirurgica"},{"issue":"15","key":"10.1002\/14651858.CD012815.pub3-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2020.03.006","article-title":"Hyperacute management of ischemic strokes: JACC Focus Seminar","volume":"75","author":"Patel","year":"2020","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3390\/nu8090578","article-title":"The use of fish oil with warfarin does not significantly affect either the international normalised ratio or incidence of adverse events in patients with atrial fibrillation and deep vein thrombosis: a retrospective study","volume":"8","author":"Pryce","year":"2016","journal-title":"Nutrients"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12944-017-0589-0","article-title":"A novel self-micro-emulsifying delivery system (SMEDS) formulation significantly improves the fasting absorption of EPA and DHA from a single dose of an omega-3 ethyl ester concentrate","volume":"16","author":"Qin","year":"2017","journal-title":"Lipids in Health and Disease"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0258|cit258","unstructured":"Review Manager (RevMan) Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0259|cit259","unstructured":"Review Manager Web (RevMan Web) Cochrane 2022"},{"issue":"9740","key":"10.1002\/14651858.CD012815.pub3-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(10)60445-X","article-title":"Cardiovascular effects of marine omega-3 fatty acids","volume":"376","author":"Saravanan","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD012815.pub3-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jama.2016.13647","article-title":"Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis","volume":"316","author":"Saver","year":"2016","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0263|cit263","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"issue":"5-6","key":"10.1002\/14651858.CD012815.pub3-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000355683","article-title":"Low serum n-3 polyunsaturated fatty acid\/n-6 polyunsaturated fatty acid ratio predicts neurological deterioration in Japanese patients with acute ischemic stroke","volume":"36","author":"Suda","year":"2013","journal-title":"Cerebrovascular Diseases (Basel, Switzerland)"},{"issue":"7","key":"10.1002\/14651858.CD012815.pub3-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1161\/STROKEAHA.107.509455","article-title":"Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients","volume":"39","author":"Tanaka","year":"2008","journal-title":"Stroke"},{"issue":"3","key":"10.1002\/14651858.CD012815.pub3-BIB0266|cit266","first-page":"246","article-title":"Marine oils; nutritional and food science relevance","volume":"36","author":"Valenzuela","year":"2009","journal-title":"Revista Chilena de Nutricion"},{"issue":"4","key":"10.1002\/14651858.CD012815.pub3-BIB0267|cit267","first-page":"383","article-title":"Docosahexaenoic acid (DHA), an essential fatty acid at the brain","volume":"40","author":"Valenzuela","year":"2013","journal-title":"Revista Chilena de Nutricion"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.nbd.2014.04.014","article-title":"Omega-3 polyunsaturated fatty acids enhance cerebral angiogenesis and provide long-term protection after stroke","volume":"68","author":"Wang","year":"2014","journal-title":"Neurobiology of Disease"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0269|cit269","volume-title":"SF-36 Health Survey Manual & Interpretation Guide","author":"Ware","year":"1993"},{"issue":"2","key":"10.1002\/14651858.CD012815.pub3-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3892\/mmr.2013.1543","article-title":"Neuroprotectin D1 attenuates brain damage induced by transient middle cerebral artery occlusion in rats through TRPC6\/CREB pathways","volume":"8","author":"Yao","year":"2013","journal-title":"Molecular Medicine Reports"},{"issue":"9567","key":"10.1002\/14651858.CD012815.pub3-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jneuroim.2014.11.007","article-title":"Omega-3 polyunsaturated fatty acids ameliorate neuroinflammation and mitigate ischemic stroke damage through interactions with astrocytes and microglia","volume":"278","author":"Zendedel","year":"2015","journal-title":"Journal of Neuroimmunology"},{"issue":"5","key":"10.1002\/14651858.CD012815.pub3-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1006\/pmed.1998.0472","article-title":"Fish consumption and mortality from all causes, ischemic heart disease, and stroke: an ecological study","volume":"28","author":"Zhang","year":"1999","journal-title":"Preventive Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012815.pub3-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1523\/JNEUROSCI.4043-13.2014","article-title":"Omega-3 fatty acids protect the brain against ischemic injury by activating Nrf2 and upregulating heme oxygenase 1","volume":"34","author":"Zhang","year":"2014","journal-title":"Journal of Neuroscience"},{"key":"10.1002\/14651858.CD012815.pub3-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.expneurol.2015.03.005","article-title":"Dietary supplementation with omega-3 polyunsaturated fatty acids robustly promotes neurovascular restorative dynamics and improves neurological functions after stroke","volume":"272","author":"Zhang","year":"2015","journal-title":"Experimental Neurology"},{"issue":"6","key":"10.1002\/14651858.CD012815.pub3-BIB0276|cit276","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012815.pub2","article-title":"Marine-derived n-3 fatty acids therapy for stroke","author":"Alvarez Campano","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T01:54:19Z","timestamp":1727488459000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012815.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Stroke Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":276,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012815.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]}}}